FASN Protein Overexpression Indicates Poor Biochemical Recurrence-Free Survival in Prostate Cancer

Figure 1

mRNA expression of FASN in TCGA public database (a–c), our sequencing data (d–f), GSE46602 (g, h), and GSE6752 (i). FASN expressions comparison between tumor and benign prostate tissue (a, d, g). FASN relative expression pattern among lymph node categories (c, f) and tumor stages (b, e, h). Comparison of FASN expression in primary prostate tumor tissue and metastasis (i) (note: T2: tumor stage 2; T3: tumor stage 3; T4: tumor stage 4; pN0: pathology lymph nodes 0; pN1: pathology lymph nodes 1).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)